English

BioStock: Saniona's CEO on year-end results and the company's long-term goals

Report this content

In 2020 Saniona laid a solid foundation in transforming the company, from discovery phase focusing on out-licensing its molecules, to a fully-integrated pharmaceutical company with the funding and expertise needed to bring its proprietary products to market. Already in 2021, the progress of Saniona’s primary drug candidate Tesomet in two rare diseases stands out, coupled with positive feedback from the FDA on the regulatory path forward. BioStock spoke with CEO Rami Levin about the company’s Q4 and year-end report and what the strategy to advance the company to the next stage forward looks like. 

Read the full interview with Rami Levin at biostock.se:

https://www.biostock.se/en/sanionas-ceo-on-year-end-results-and-the-companys-long-term-goals/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Documents & Links

Quick facts

BioStock: Saniona's CEO on year-end results and the company's long-term goals
Tweet this

Quotes

With a clear path forward for Tesomet in HO and PWS, we look forward to initiating our phase IIb trials in the first half of this year, as planned. We also plan to initiate a phase I trial of SAN711 in the first half. Further, our partner Medix has stated that they are confident that the Mexican health authority’s review of tesofensine for weight management is moving forward, and they expect a decision in early 2021
Rami Levin, CEO Saniona